Published in Hepatology on December 16, 2016
COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res (2014) 10.77
Ras oncogenes: split personalities. Nat Rev Mol Cell Biol (2008) 7.91
Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell (2005) 7.75
Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology (2006) 3.95
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci (2011) 3.89
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res (2009) 3.77
Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer (2016) 2.91
Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. Nature (2014) 2.77
Conditional deletion of beta-catenin reveals its role in liver growth and regeneration. Gastroenterology (2006) 2.54
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol (2009) 2.42
New targets of beta-catenin signaling in the liver are involved in the glutamine metabolism. Oncogene (2002) 2.23
Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet (2015) 2.17
Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas. Oncogene (2006) 1.84
Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma. Cancer Res (2012) 1.83
Accelerated liver regeneration and hepatocarcinogenesis in mice overexpressing serine-45 mutant beta-catenin. Hepatology (2010) 1.71
Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. Gastroenterology (2015) 1.52
Complete response of Ctnnb1-mutated tumours to β-catenin suppression by locked nucleic acid antisense in a mouse hepatocarcinogenesis model. J Hepatol (2014) 1.50
Hydrodynamic transfection for generation of novel mouse models for liver cancer research. Am J Pathol (2014) 1.44
Oncogenic β-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice. J Clin Invest (2012) 1.24
β-Catenin Signaling and Roles in Liver Homeostasis, Injury, and Tumorigenesis. Gastroenterology (2015) 1.20
Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma. Nat Cell Biol (2015) 1.17
The global decrease in cancer mortality: trends and disparities. Ann Oncol (2016) 1.08
L-Asparaginase and inhibitors of glutamine synthetase disclose glutamine addiction of β-catenin-mutated human hepatocellular carcinoma cells. Curr Cancer Drug Targets (2011) 0.96
Glutamine depletion by crisantaspase hinders the growth of human hepatocellular carcinoma xenografts. Br J Cancer (2014) 0.92
β-catenin activation in a novel liver progenitor cell type is sufficient to cause hepatocellular carcinoma and hepatoblastoma. Cancer Res (2014) 0.91
Beta-catenin regulates vitamin C biosynthesis and cell survival in murine liver. J Biol Chem (2009) 0.91
Nanotechnological carriers for cancer chemotherapy: the state of the art. Colloids Surf B Biointerfaces (2015) 0.88
The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications. Eur J Clin Invest (2015) 0.86
Role of leukocyte cell-derived chemotaxin 2 as a biomarker in hepatocellular carcinoma. PLoS One (2014) 0.83
SKP2 cooperates with N-Ras or AKT to induce liver tumor development in mice. Oncotarget (2015) 0.81
Modeling a human hepatocellular carcinoma subset in mice through coexpression of met and point-mutant β-catenin. Hepatology (2016) 0.81
Postponing the Hypoglycemic Response to Partial Hepatectomy Delays Mouse Liver Regeneration. Am J Pathol (2016) 0.79
Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin. Mol Cancer Ther (2016) 0.77